Immuron Limited Sponsored ADR
(NASDAQ : IMRN)

( )
IMRN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.05%87.301.3%$1275.26m
AMGNAmgen Inc.
-0.25%198.891.2%$667.61m
GILDGilead Sciences, Inc.
-1.28%67.640.9%$577.79m
BIIBBiogen Inc.
-1.63%332.031.3%$485.41m
LOXOLoxo Oncology Inc
-0.18%233.2612.7%$449.60m
ILMNIllumina, Inc.
0.05%305.633.5%$350.96m
VRTXVertex Pharmaceuticals Incorporated
-0.28%186.151.9%$318.23m
REGNRegeneron Pharmaceuticals, Inc.
-0.12%404.542.6%$308.69m
ALXNAlexion Pharmaceuticals, Inc.
-0.03%111.702.0%$229.47m
TSROTESARO, Inc.
0.03%74.8814.4%$201.67m
AAgilent Technologies, Inc.
-0.82%70.021.5%$164.25m
EXASExact Sciences Corporation
-2.75%74.9725.3%$151.07m
INCYIncyte Corporation
-2.79%76.562.5%$146.84m
SRPTSarepta Therapeutics, Inc.
0.45%119.2615.4%$142.24m
LGNDLigand Pharmaceuticals Incorporated
-16.48%110.0523.1%$105.44m

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the R&D projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers company activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.